Details

Autor(en) / Beteiligte

• Shields, Adrian M.
• Burns, Siobhan O.
• Savic, Sinisa
• Richter, Alex G.
• Anantharachagan, Ariharan
• Arumugakani, Gururaj
• Baker, Kenneth
• Bahal, Sameer
• Bermingham, William
• Bhole, Malini
• Boules, Evon
• Bright, Philip
• Burns, Siobhan
• Cleave, Betsy
• Dempster, John
• Devlin, Lisa
• Dhalla, Fatima
• Drewe, Elizabeth
• Duncan, Christopher
• Dziadzio, Magdalena
• Elkhalifa, Shuayb
• Gennery, Andrew
• Goddard, Sarah
• Grigoriadou, Sofia
• Hayman, Grant
• Herwadkar, Archana
• Huissoon, Aarnoud
• Jain, Rashmi
• Jolles, Stephen
• Johnston, Sarah
• Leeman, Lucy
• Mahabir, Shanti
• MacLochlainn, Dylan
• McDermott, Elizabeth
• Misbah, Siraj
• Morsi, Hadeil
• Murng, Sai
• Noorani, Sadia
• O’Brien, Rachael
• Patel, Smita
• Price, Arthur
• Richter, Alex
• Seneviratne, Suranjith
• Shields, Adrian
• Shrimpton, Anna
• Stroud, Catherine
• Vaitla, Prashantha
• Verma, Nisha

Titel

COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience

Ist Teil von

• Journal of allergy and clinical immunology, 2021-03, Vol.147 (3), p.870-875.e1

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• As of November 2020, severe acute respiratory syndrome coronavirus 2 has resulted in 55 million infections worldwide and more than 1.3 million deaths from coronavirus disease 2019 (COVID-19). Outcomes following severe acute respiratory syndrome coronavirus 2 infection in individuals with primary immunodeficiency (PID) or symptomatic secondary immunodeficiency (SID) remain uncertain. We sought to document the outcomes of individuals with PID or symptomatic SID following COVID-19 in the United Kingdom. At the start of the COVID-19 pandemic, the United Kingdom Primary Immunodeficiency Network established a registry of cases to collate the nationwide outcomes of COVID-19 in individuals with PID or symptomatic SID and determine risk factors associated with morbidity and mortality from COVID-19 in these patient groups. A total of 100 patients had been enrolled by July 1, 2020, 60 with PID, 7 with other inborn errors of immunity including autoinflammatory diseases and C1 inhibitor deficiency, and 33 with symptomatic SID. In individuals with PID, 53.3% (32 of 60) were hospitalized, the infection-fatality ratio was 20.0% (12 of 60), the case-fatality ratio was 31.6% (12 of 38), and the inpatient mortality was 37.5% (12 of 32). Individuals with SID had worse outcomes than those with PID; 75.8% (25 of 33) were hospitalized, the infection-fatality ratio was 33.3% (11 of 33), the case-fatality ratio was 39.2% (11 of 28), and inpatient mortality was 44.0% (11 of 25). In comparison to the general population, adult patients with PID and symptomatic SID display greater morbidity and mortality from COVID-19. This increased risk must be reflected in public health guidelines to adequately protect vulnerable patients from exposure to the virus.